Syndax Pharmaceuticals, Inc.
SNDX Healthcare Biotechnology
Syndax Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $172.4 million, up 627.8% from fiscal 2024. In the quarter to June 2026, revenue grew 91.8%, EPS grew 33.7%, free cash flow grew 65.5% and total debt rose 71.0%, each against the same quarter a year earlier.
Follow SNDX
Syndax Pharmaceuticals, Inc. (SNDX) Piotroski F-score
Syndax Pharmaceuticals, Inc.'s Piotroski F-score for fiscal 2025 cannot be worked out: needs three fiscal years.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2021 | 7 | 4.00 |
| FY2020 | 3 | 1.00 |
| FY2019 | 2 | 0.00 |
| FY2018 | 2 | (1.00) |
| FY2017 | 3 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (45.50%) | — | Fail | 0 |
| Positive operating cash flow | (322.98m) | (274.90m) | Fail | 0 |
| Rising return on assets | (45.50%) | — | n/a | — |
| Cash flow above net income | (37.56m) | 43.86m | Fail | 0 |
| Falling long-term leverage | 0.55 | — | n/a | — |
| Rising current ratio | 4.40 | 5.82 | Fail | 0 |
| No new shares issued | 86,625,600 | 85,622,100 | Fail | 0 |
| Rising gross margin | 95.96% | 96.51% | Fail | 0 |
| Rising asset turnover | 0.27 | — | n/a | — |
| Piotroski F-score | n/a — needs three fiscal years | — | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| TSHA Taysha Gene Therapies, Inc. compare | 4 |
| NKTR Nektar Therapeutics compare | 3 |
| LBRX LB Pharmaceuticals Inc compare | — |
| GHRS GH Research PLC compare | — |
| DMRA Galecto, Inc. compare | — |
| VOR Vor Biopharma Inc. compare | — |
| BCAX Bicara Therapeutics Inc. compare | — |
| DRTS Alpha Tau Medical Ltd. compare | — |
| SNDX Syndax Pharmaceuticals, Inc. | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover